Stockreport

Inhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent Activity

Inhibikase Therapeutics, Inc.  (IKT) 
PDF BOSTON, March 27, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company innovating [Read more]